8 results
1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1…
To prospectively study if patients carrying clinically relevant DPYD variants (DPYD*2A, c.2846A>T, c.1236G>A/HapB3, c.1679T>G) are more at risk for developing moderate/severe vesicles or bullae with 5-FU cream.
There might be discrepancies in number and type of Cancer Predisposition Syndrome diagnoses between the genotype first and the phenotype first approach.
Mainstreaming of germline genetic tests in regular healthcare is feasible for healthcare professionals and acceptable for both patients and healthcare professionals
In the current study, biomarkers for tumor and immune response during radium-223 are evaluated, thereby potentially contributing to a better understanding of immune responses during radium-223 and the rational design of future treatment strategies…
The hypothesis investigated is that a correct diagnosis (including subclassification of the tumor) and prognosis can be made more rapidly and that monitoring tumor development in response to therapy is more precise when adding tumor markers to the…
To analyze the number of patients with (germline/somatic) actionable molecular aberrations in patients with relapsed/refractory pediatric tumors for whom no standard treatment or study protocol is available.
The rationale of this study was to investigate the alteration of colonic motor patterns in the early postoperative stage and between patients with no or minor LARS-symptoms (LARS-score < 30) compared to patients experiencing major LARS…